Oncorus Announces Proposed Public Offering of Common Stock
February 09, 2021 17:01 ET
|
Oncorus, Inc.
CAMBRIDGE, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company developing next-generation, systemically active viral immunotherapies to...
Oncorus Announces Publication of Preclinical Data Demonstrating Potent Systemic Antitumor Activity of its Clinical Stage Oncolytic Herpes Simplex Viral Immunotherapy Product Candidate ONCR-177
January 20, 2021 07:00 ET
|
Oncorus, Inc.
-- Preclinical findings show that ONCR-177’s systemic antitumor immunity is driven by its five complementary immunomodulatory transgene payloads and retention of γ34.5 -- -- Complete and durable...
Oncorus to Build GMP Viral Immunotherapy Clinical Manufacturing Facility in Andover, Mass.
January 04, 2021 07:00 ET
|
Oncorus, Inc.
-- 88,000 square foot state-of-the-art facility will support Oncorus’ advancing, multi-product pipeline of intratumorally and intravenously administered viral immunotherapies – -- Initial phase of...
Oncorus Appoints Scott Canute to its Board of Directors
December 14, 2020 08:00 ET
|
Oncorus, Inc.
CAMBRIDGE, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company developing next-generation viral immunotherapies to transform outcomes...
Oncorus Appoints Steve Harbin as Chief Operating Officer and Chief of Staff
December 07, 2020 08:00 ET
|
Oncorus, Inc.
CAMBRIDGE, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company developing next-generation viral immunotherapies to transform outcomes...
Oncorus to Participate in Fireside Chats at Upcoming Piper Sandler Annual Healthcare Conference and Evercore ISI HealthCONx Conference
November 24, 2020 08:00 ET
|
Oncorus, Inc.
CAMBRIDGE, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq:ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, announced...
Oncorus to Present at Upcoming Jefferies Virtual London Healthcare Conference
November 12, 2020 07:00 ET
|
Oncorus, Inc.
CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq:ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, announced...
Oncorus Reports Third Quarter 2020 Financial Results and Provides Business Highlights
November 11, 2020 07:00 ET
|
Oncorus, Inc.
-- Received $98.4 million in aggregate gross proceeds in October from initial public offering -- -- Initiated Phase 1 clinical trial of lead viral immunotherapy candidate, ONCR-177, for the...
Oncorus to Present at Chardan 4th Annual Genetic Medicines Conference
October 05, 2020 16:05 ET
|
Oncorus, Inc.
CAMBRIDGE, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company focused on developing next-generation viral immunotherapies to transform...
Oncorus Announces Pricing of Initial Public Offering
October 01, 2020 19:12 ET
|
Oncorus, Inc.
CAMBRIDGE, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Oncorus, Inc., a clinical stage biopharmaceutical company focused on developing next-generation viral immunotherapies to transform outcomes for...